Healthcare Industry News: kidney disease
News Release - February 14, 2011
AlloCure Appoints Kevin J. Heyeck as Chief Business OfficerBURLINGTON, Mass.--(Healthcare Sales & Marketing Network)-- AlloCure Inc., a biotechnology company developing innovative therapies for the treatment of kidney disease, today announced the appointment of Kevin J. Heyeck as Chief Business Officer. Mr. Heyeck, who brings more than twenty years of experience in business development leadership and corporate partnering for emerging pharmaceutical companies, previously led business development efforts at Vitae Pharmaceuticals, and before that, Pharmacopeia.
“Kevin Heyeck has a very impressive track record in business development, and he has been responsible for many major partnerships with large pharmaceutical and biotechnology companies worldwide,” said Robert M. Brenner, M.D., AlloCure’s President and Chief Executive Officer. “We are delighted to welcome Kevin to the AlloCure management team. Kevin’s arrival marks an important milestone in AlloCure’s evolution as we advance into later stage clinical development and chart the course for future commercialization of our novel treatment for acute kidney injury.”
“kidney disease is a significant social and economic societal burden. Approximately 2-3 million people in the United States experience acute kidney injury (AKI) each year, which contributes to chronic kidney disease, end-stage renal disease (ESRD), and too often, death,” said Mr. Heyeck. “The lack of therapies to prevent and treat AKI makes this condition a critical area of unmet medical need. AlloCure has made great strides in advancing its investigational treatment for AKI towards clinical proof-of-concept, and I look forward to working with the talented team at AlloCure to realize the promise of this new therapeutic approach for patients in need.”
Prior to joining AlloCure, Kevin Heyeck was Vice President, Business Development at Vitae Pharmaceuticals where he was responsible for securing multiple major partnerships in areas of Alzheimer’s disease, diabetes and hypertension. Prior to Vitae, Mr. Heyeck headed business development for Pharmacopeia, a pioneer in the use of combinatorial chemistry in drug discovery, where he was responsible for over 20 partnerships with pharmaceutical and biotechnology companies worldwide. Prior to Pharmacopeia, Mr. Heyeck was Technology Transfer Officer at Harvard University. He received his B.A. degree at the University of California, Santa Cruz.
About Acute Kidney Injury and Chronic kidney disease
Acute kidney injury (AKI) is a serious medical condition and is associated with considerable morbidity, mortality and healthcare costs. There are currently no effective treatment options to prevent or treat AKI, other than supportive measures, including dialysis. Acute kidney injury can lead to a progression of chronic kidney disease, ESRD, and death. Twenty-three million Americans suffer from chronic kidney disease, 500 thousand of whom have ESRD. kidney disease and its complications account for approximately 20% of the annual Medicare budget.
AlloCure is a privately held, venture-funded company focused on the treatment of kidney disease. The company has made great progress in the development of the first effective cell therapy for the treatment of kidney diseases as well as other unmet medical needs. The company’s headquarters is located in Burlington, MA, and the company maintains facilities in Salt Lake City, UT. For more information about AlloCure, please visit the company’s web site at http://www.allocure.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.